Page last updated: 2024-12-09

desmethylclomipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desmethylclomipramine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID622606
CHEBI ID124969
SCHEMBL ID11384662
MeSH IDM0059196

Synonyms (25)

Synonym
norchlorimipramine
norclomipramine
desmethylclomipramine
CHEBI:124969
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n-methylpropan-1-amine
303-48-0
n-demethylclomipramine
demethylchlorimipramine
desmethylchlorimipramine
unii-01dn47ppqg
01dn47ppqg ,
3-chloro-10,11-dihydro-n-methyl-5h-dibenz(b,f)azepine-5-propanamine
5h-dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-n-methyl-
BRD-K52696183-003-01-0
gp-38025
desmethylclomipramine [who-dd]
SCHEMBL11384662
aminoguanidinecarbonate
3-(3-chloro-10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n-methyl-1-propanamine #
VPIXQGUBUKFLRF-UHFFFAOYSA-N
Q27215299
5h-dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-n-methyl-
3-(3-chloro-10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n-methylpropan-1-amine
DTXSID70952663
AS-80832

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" EEG, ECG, and laboratory parameters and adverse effects reported by the patients, as well as global clinical improvement, were assessed."( Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Härtter, S; Hiemke, C; Leal, M; Szegedi, A; Wetzel, H, 1996
)
0.29

Pharmacokinetics

Clomipramine is one of the drugs for depression during pregnancy. pharmacokinetic data of clomiphamine and its active metabolite desmethylclomipamine in this vulnerable period are lacking.

ExcerptReferenceRelevance
" The pharmacokinetic parameters of both molecules were determined in brain tissue and plasma."( Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1).
Advenier, C; Bastide, P; Bulach, C; Cordonnier, P; Duroux, E; Eschalier, A; Fialip, J; Marty, H; Pays, M; Varoquaux, O, 1992
)
0.28
" We propose a means of standardizing the pattern of administration for any particular animal, based on a pharmacokinetic study of the antidepressant [here clomipramine (CMI)] in that animal."( Pharmacokinetic patterns of repeated administration of antidepressants in animals. I. Implications for antinociceptive action of clomipramine in mice.
Bastide, P; Eschalier, A; Fialip, J; Makambila, MC; Marty, H; Varoquaux, O, 1988
)
0.27
"The pharmacokinetic profiles of clomipramine (CMP) and the serial changes of its concentration in specific brain regions were investigated in rats after an acute treatment with intravenous CMP (10 mg/kg)."( A pharmacokinetic study of clomipramine in regions of the brain.
Kido, H; Kishitani, K; Kurachi, M; Kurata, K; Yamaguchi, N, 1986
)
0.27
" No correlation between pharmacokinetic and improvement parameters could be found."( Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients.
Jungkunz, G; Kuss, HJ, 1986
)
0.27
"The pharmacokinetic profiles for chlorimipramine (CIM) and its demethylated metabolite desmethylchlorimipramine (DCIM) in blood and in specific brain regions were obtained in rats after acute or chronic treatment with 15 mg/kg of the tricyclic antidepressant CIM."( Pharmacokinetics of chlorimipramine and its demethylated metabolite in blood and brain regions of rats treated acutely and chronically with chlorimipramine.
Cooper, TB; Friedman, E, 1983
)
0.27
" Various pharmacokinetic parameters were then determined."( The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
Ball, RO; Conlon, PD; Hewson, CJ; Luescher, UA, 1998
)
0.57
" Terminal half-life increased slightly (1."( Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration.
Altmann, BO; King, JN; Maurer, MP; Strehlau, GA, 2000
)
0.31
"Because metabolites play a major role in the clinical response to clomipramine, the objective of the current study was to develop a population model and evaluate its performance to describe the pharmacokinetic profiles of clomipramine (C) and its active metabolites desmethylclomipramine (DC), 8-hydroxy-clomipramine (OHC) and 8-hydroxy-desmethylclomipramine (OHDC)."( Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation.
Balant, LP; Bechtel, PR; Bizouard, P; Gex-Fabry, M; Haffen, E; Paintaud, G; Sechter, D, 2000
)
0.75
"09 h(-1) from which a mean half-life of 12."( Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats.
Doucet, M; Frank, D; Intorre, L; Lainesse, C; Meucci, V; Soldani, G, 2006
)
0.61
"Clomipramine is one of the drugs for depression during pregnancy; however, pharmacokinetic data of clomipramine and its active metabolite desmethylclomipramine in this vulnerable period are lacking."( Pharmacokinetics of clomipramine during pregnancy.
de Jong-van de Berg, LT; Proost, JH; Smit, JP; Ter Horst, PG; Vries, MT; Wilffert, B, 2015
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Although the bioavailability of parenteral clomipramine was greater, there were no significant differences in either efficacy or side effects between the two groups."( Acute antidepressant effect following pulse loading with intravenous and oral clomipramine.
Kupfer, DJ; Nathan, RS; Perel, JM; Pollock, BG, 1989
)
0.28
" Values for mean residence time and terminal half-life following oral administration were similar to values obtained following IV administration, and systemic bioavailability was approximately 20% for clomipramine and 140% for desmethylclomipramine, indicating fast absorption of clomipramine from the gastrointestinal tract and extensive first-pass metabolism."( Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration.
Fisch, RD; Hotz, RP; King, JN; Maurer, MP, 2000
)
0.49
" Clomipramine bioavailability was 90%."( Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats.
Doucet, M; Frank, D; Intorre, L; Lainesse, C; Meucci, V; Soldani, G, 2006
)
0.61

Dosage Studied

ExcerptRelevanceReference
" For the remaining 29, a comparison with 29 Caucasian patients treated by clomipramine (the two samples are matched for sex and age, and the variables of weight, dosage and drug association are controlled) shows no significantly higher plasma levels in the Beninese sample."( Clomipramine plasma levels among depressed outpatients in Benin, west Africa: drug compliance and comparison with Caucasian patients.
Bertschy, G; Vandel, S, 1992
)
0.28
"A double-blind, randomized trial of oral vs intravenous clomipramine hydrochloride pulse-loading dosing regimens was conducted."( Acute antidepressant effect following pulse loading with intravenous and oral clomipramine.
Kupfer, DJ; Nathan, RS; Perel, JM; Pollock, BG, 1989
)
0.28
"001), indicating a less dose-response in the latter."( A relationship between clomipramine brain concentration and its effect on serotonin metabolism.
Kido, H; Kishitani, K; Kurachi, M; Kurata, K; Yamaguchi, N, 1988
)
0.27
" Doubling of the dosage leads to 3 fold chlorimipramine and 4 fold desmethylchlorimipramine concentrations."( Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients.
Jungkunz, G; Kuss, HJ, 1986
)
0.27
" In contrast, in 7 other patients receiving a dosage increasing to 150 mg per day at Day 7, mean plasma levels of C1 and DMC1 continued to rise during the entire treatment period."( Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.
Allers, G; Jounet, JM; Vandel, B; Vandel, S; Volmat, R, 1982
)
0.5
"Two different initial dosing regimens with clomipramine (CMI) were compared with particular attention to early response indicators."( Early response patterns associated with successful clomipramine treatment.
Bowler, KA; Kupfer, DJ; Miewald, JM; Perel, JM; Pollock, BG, 1993
)
0.29
" In addition, 'peak' and 'trough' samples were taken throughout the 28-day dosing period."( The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
Ball, RO; Conlon, PD; Hewson, CJ; Luescher, UA, 1998
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzoazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Clomipramine Metabolism Pathway414

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (48.05)18.7374
1990's22 (28.57)18.2507
2000's10 (12.99)29.6817
2010's8 (10.39)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.03 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (14.12%)5.53%
Reviews2 (2.35%)6.00%
Case Studies9 (10.59%)4.05%
Observational0 (0.00%)0.25%
Other62 (72.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]